150 related articles for article (PubMed ID: 11279110)
1. Requirement for HDM2 activity in the rapid degradation of p53 in neuroblastoma.
Isaacs JS; Saito S; Neckers LM
J Biol Chem; 2001 May; 276(21):18497-506. PubMed ID: 11279110
[TBL] [Abstract][Full Text] [Related]
2. HDM2 impairs Noxa transcription and affects apoptotic cell death in a p53/p73-dependent manner in neuroblastoma.
Shi Y; Takenobu H; Kurata K; Yamaguchi Y; Yanagisawa R; Ohira M; Koike K; Nakagawara A; Jiang LL; Kamijo T
Eur J Cancer; 2010 Aug; 46(12):2324-34. PubMed ID: 20591651
[TBL] [Abstract][Full Text] [Related]
3. Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during down-regulation of the p53 response after multiple types of DNA damage.
Joseph TW; Zaika A; Moll UM
FASEB J; 2003 Sep; 17(12):1622-30. PubMed ID: 12958168
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
Ghosh M; Huang K; Berberich SJ
Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
[TBL] [Abstract][Full Text] [Related]
5. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway.
Zhang Y; Wolf GW; Bhat K; Jin A; Allio T; Burkhart WA; Xiong Y
Mol Cell Biol; 2003 Dec; 23(23):8902-12. PubMed ID: 14612427
[TBL] [Abstract][Full Text] [Related]
6. Supramolecular complex formation between Rad6 and proteins of the p53 pathway during DNA damage-induced response.
Lyakhovich A; Shekhar MP
Mol Cell Biol; 2003 Apr; 23(7):2463-75. PubMed ID: 12640129
[TBL] [Abstract][Full Text] [Related]
7. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.
Fan YH; Cheng J; Vasudevan SA; Dou J; Zhang H; Patel RH; Ma IT; Rojas Y; Zhao Y; Yu Y; Zhang H; Shohet JM; Nuchtern JG; Kim ES; Yang J
Cell Death Dis; 2013 Oct; 4(10):e867. PubMed ID: 24136231
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma.
Lau L; Hansford LM; Cheng LS; Hang M; Baruchel S; Kaplan DR; Irwin MS
Oncogene; 2007 Mar; 26(13):1920-31. PubMed ID: 16983334
[TBL] [Abstract][Full Text] [Related]
9. p53 promotes its own polyubiquitination by enhancing the HDM2 and HDMX interaction.
Medina-Medina I; Martínez-Sánchez M; Hernández-Monge J; Fahraeus R; Muller P; Olivares-Illana V
Protein Sci; 2018 May; 27(5):976-986. PubMed ID: 29524278
[TBL] [Abstract][Full Text] [Related]
10. Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2.
Meulmeester E; Maurice MM; Boutell C; Teunisse AF; Ovaa H; Abraham TE; Dirks RW; Jochemsen AG
Mol Cell; 2005 May; 18(5):565-76. PubMed ID: 15916963
[TBL] [Abstract][Full Text] [Related]
11. Alterations in gene expression and sensitivity to genotoxic stress following HdmX or Hdm2 knockdown in human tumor cells harboring wild-type p53.
Heminger K; Markey M; Mpagi M; Berberich SJ
Aging (Albany NY); 2009 Jan; 1(1):89-108. PubMed ID: 19946469
[TBL] [Abstract][Full Text] [Related]
12. ATM complexes with HDM2 and promotes its rapid phosphorylation in a p53-independent manner in normal and tumor human cells exposed to ionizing radiation.
de Toledo SM; Azzam EI; Dahlberg WK; Gooding TB; Little JB
Oncogene; 2000 Dec; 19(54):6185-93. PubMed ID: 11175332
[TBL] [Abstract][Full Text] [Related]
13. Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors.
Lai Z; Yang T; Kim YB; Sielecki TM; Diamond MA; Strack P; Rolfe M; Caligiuri M; Benfield PA; Auger KR; Copeland RA
Proc Natl Acad Sci U S A; 2002 Nov; 99(23):14734-9. PubMed ID: 12407176
[TBL] [Abstract][Full Text] [Related]
14. Cytoplasmically "sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation.
Zaika A; Marchenko N; Moll UM
J Biol Chem; 1999 Sep; 274(39):27474-80. PubMed ID: 10488081
[TBL] [Abstract][Full Text] [Related]
15. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.
Lu J; Guan S; Zhao Y; Yu Y; Wang Y; Shi Y; Mao X; Yang KL; Sun W; Xu X; Yi JS; Yang T; Yang J; Nuchtern JG
Oncotarget; 2016 Dec; 7(50):82757-82769. PubMed ID: 27764791
[TBL] [Abstract][Full Text] [Related]
16. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation.
Kurki S; Peltonen K; Latonen L; Kiviharju TM; Ojala PM; Meek D; Laiho M
Cancer Cell; 2004 May; 5(5):465-75. PubMed ID: 15144954
[TBL] [Abstract][Full Text] [Related]
17. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53.
Linares LK; Hengstermann A; Ciechanover A; Müller S; Scheffner M
Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12009-14. PubMed ID: 14507994
[TBL] [Abstract][Full Text] [Related]
18. Allosteric Interactions by p53 mRNA Govern HDM2 E3 Ubiquitin Ligase Specificity under Different Conditions.
Medina-Medina I; García-Beltrán P; de la Mora-de la Mora I; Oria-Hernández J; Millot G; Fahraeus R; Reyes-Vivas H; Sampedro JG; Olivares-Illana V
Mol Cell Biol; 2016 Aug; 36(16):2195-205. PubMed ID: 27215386
[TBL] [Abstract][Full Text] [Related]
19. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53.
Tao W; Levine AJ
Proc Natl Acad Sci U S A; 1999 Mar; 96(6):3077-80. PubMed ID: 10077639
[TBL] [Abstract][Full Text] [Related]
20. Regulation of HDM2 activity by the ribosomal protein L11.
Lohrum MA; Ludwig RL; Kubbutat MH; Hanlon M; Vousden KH
Cancer Cell; 2003 Jun; 3(6):577-87. PubMed ID: 12842086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
